CLOs on the Move

Abattis

www.abattis.com

 
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.abattis.com
  • 885 Burrard Street Suite 1040
    Vancouver, BC CAN V6C 3E8
  • Phone: 604.538.6650

Executives

Name Title Contact Details

Similar Companies

Kiniksa Pharmaceuticals

Our Story Kiniksa’s goal is to build a fully-integrated biopharmaceutical company. Our management team and employees are focused on advancing a portfolio of immune-modulating, clinical-stage product candidates that target underserved conditions and off...

Southwest Foundation For Biomedical Research

Southwest Foundation For Biomedical Research is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Institute for Clinical Evaluative Sciences

Institute for Clinical Evaluative Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cultiv8 Hemp Solutions

Cultiv8 Hemp Solutions, Inc. specializes in the growth and harvest of industrial hemp. We manufacture biodegradable paper and plastic alternatives, as well as biofuel, protien, and biomass.

Providence Therapeutics

Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.